CR20180118A - Composiciones de insulina de rápida acción - Google Patents

Composiciones de insulina de rápida acción

Info

Publication number
CR20180118A
CR20180118A CR20180118A CR20180118A CR20180118A CR 20180118 A CR20180118 A CR 20180118A CR 20180118 A CR20180118 A CR 20180118A CR 20180118 A CR20180118 A CR 20180118A CR 20180118 A CR20180118 A CR 20180118A
Authority
CR
Costa Rica
Prior art keywords
quick action
insulin compositions
action insulin
insulin analog
insulin
Prior art date
Application number
CR20180118A
Other languages
English (en)
Inventor
Chi A Nguyen
Michael Edward Christe
Nanette Elizabeth Schulte
Thomas Andrew Hardy
Ranajoy Majumdar
Virender Kumar Sarin
Michael Patrick Akers
Chad D Paavola
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57003563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20180118(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20180118A publication Critical patent/CR20180118A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Abstract

La presente invención se refiere a una composición farmacéutica de insulina humana o análogo de insulina que incluye citrato, treprostinilo y agentes estabilizantes, que tiene acción farmacocinética y farmacodinámica más rápida que las formulaciones comerciales de productos análogos de insulina existentes y que es estable para uso comercial
CR20180118A 2015-08-27 2016-08-19 Composiciones de insulina de rápida acción CR20180118A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562210469P 2015-08-27 2015-08-27
PCT/US2016/047723 WO2017034956A1 (en) 2015-08-27 2016-08-19 Rapid-acting insulin compositions

Publications (1)

Publication Number Publication Date
CR20180118A true CR20180118A (es) 2018-03-20

Family

ID=57003563

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20180118A CR20180118A (es) 2015-08-27 2016-08-19 Composiciones de insulina de rápida acción

Country Status (39)

Country Link
US (3) US9901623B2 (es)
EP (2) EP3340966B1 (es)
JP (2) JP6359780B2 (es)
KR (1) KR102018998B1 (es)
CN (1) CN107920992B (es)
AR (1) AR105712A1 (es)
AU (1) AU2016310475B2 (es)
BR (1) BR112018001755A2 (es)
CA (1) CA2994427C (es)
CL (1) CL2018000503A1 (es)
CO (1) CO2018002026A2 (es)
CR (1) CR20180118A (es)
DK (1) DK3340966T3 (es)
DO (1) DOP2018000059A (es)
EA (1) EA033396B1 (es)
EC (1) ECSP18014922A (es)
ES (1) ES2928664T3 (es)
FI (1) FI3340966T3 (es)
HR (1) HRP20221367T1 (es)
HU (1) HUE060626T2 (es)
IL (1) IL256939B (es)
JO (1) JO3749B1 (es)
LT (1) LT3340966T (es)
MA (1) MA42701B1 (es)
MD (1) MD3340966T2 (es)
MX (1) MX2018002482A (es)
MY (1) MY195781A (es)
NZ (1) NZ739338A (es)
PE (1) PE20180782A1 (es)
PH (1) PH12018500422A1 (es)
PL (1) PL3340966T3 (es)
PT (1) PT3340966T (es)
RS (1) RS63731B1 (es)
SV (1) SV2018005643A (es)
TN (1) TN2018000056A1 (es)
TW (1) TWI614025B (es)
UA (1) UA120142C2 (es)
WO (1) WO2017034956A1 (es)
ZA (1) ZA201800511B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX360107B (es) 2012-11-13 2018-10-23 Adocia Formulación de acción rápida de insulina que comprende un compuesto aniónico sustituido.
AR102869A1 (es) * 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
US11207384B2 (en) * 2017-06-01 2021-12-28 Eli Lilly And Company Rapid-acting insulin compositions
WO2019050749A1 (en) * 2017-09-08 2019-03-14 Eli Lilly And Company PHARMACEUTICAL COMBINATIONS COMPRISING INSULIN AND AT LEAST ONE AGENT SELECTED AMONG MELOXICAM, BROMFENAC SODIUM, ACETYLSALICYLIC ACID, SALICYLIC ACID AND PARACETAMOL
US20210093775A1 (en) * 2018-04-04 2021-04-01 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
CA3094237A1 (en) * 2018-04-04 2019-10-10 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
EP3773473A1 (en) * 2018-04-04 2021-02-17 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
FR3083985A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
FR3083984A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
WO2019243627A1 (fr) 2018-06-23 2019-12-26 Adocia Dispositif pour injecter une solution d'insuline(s)
WO2020060823A1 (en) * 2018-09-18 2020-03-26 Eli Lilly And Company Erbumine salt of treprostinil
JP2022540862A (ja) * 2019-07-12 2022-09-20 ノヴォ ノルディスク アー／エス 高濃度インスリン製剤
WO2022002008A1 (zh) * 2020-06-30 2022-01-06 江苏恒瑞医药股份有限公司 速效胰岛素组合物及其医药用途

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2740953A1 (de) 1977-09-12 1979-03-22 Thera Ges Fuer Patente Verwendung von prostaglandinen zur senkung des blutzuckerspiegels
EP0018609B1 (de) 1979-04-30 1983-09-21 Hoechst Aktiengesellschaft Gegen Denaturierung beständige, wässrige Protein-Lösungen, Verfahren zu ihrer Herstellung und ihre Verwendung
ZA821243B (en) * 1981-03-10 1983-01-26 Novo Industri As Stabilized insulin preparation and method for their production
FI78616C (fi) 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK503386D0 (da) * 1986-10-20 1986-10-20 Novo Industri As Peptidpraeparater
AU612141B2 (en) 1987-02-25 1991-07-04 Novo Nordisk A/S Novel insulin derivatives
US5716927A (en) 1988-12-23 1998-02-10 Novo Nordisk A/S Insulin analogs having a modified B-chain
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
AUPO066096A0 (en) 1996-06-26 1996-07-18 Peptide Delivery Systems Pty Ltd Oral delivery of peptides
JPH10251146A (ja) 1997-03-11 1998-09-22 Toray Ind Inc 糖尿病性神経障害の治療方法
WO1999034821A1 (en) 1998-01-09 1999-07-15 Novo Nordisk A/S Stabilised insulin compositions
DE60000288T2 (de) 1999-01-26 2003-01-16 Lilly Co Eli Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten
EP1231907A2 (en) 1999-11-15 2002-08-21 Hanamaraddi T. Gangal Dextrose and insulin fluid formulation for intravenous infusion
US20020141946A1 (en) 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
ATE496064T1 (de) 2002-05-07 2011-02-15 Novo Nordisk As Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
CA2532807A1 (en) * 2003-07-17 2005-02-03 Cotherix, Inc. Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome
JP5190200B2 (ja) * 2003-12-16 2013-04-24 ユナイテッド セラピューティクス コーポレイション 虚血性病変の治療および予防のためのトレプロスチニルの用途
US7279457B2 (en) 2004-03-12 2007-10-09 Biodel, Inc. Rapid acting drug delivery compositions
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
WO2005099680A2 (en) * 2004-04-12 2005-10-27 United Therapeutics, Inc. Use of treprostinil to treat neuropathic diabetic foot ulcers
US20080171695A1 (en) * 2005-02-02 2008-07-17 Novo Nordisk A/S Insulin Derivatives
US8067362B2 (en) * 2005-02-02 2011-11-29 Novo Nordisk As Insulin derivatives
US20070086952A1 (en) 2005-09-29 2007-04-19 Biodel, Inc. Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
JP2009509539A (ja) * 2005-09-30 2009-03-12 パーレジェン サイエンシーズ， インコーポレイテッド 血糖調節の障害のスクリーニングおよび処置のための方法および組成物
DE102006047538A1 (de) * 2006-10-07 2008-04-10 Sanofi-Aventis Deutschland Gmbh Medikamentendosiersystem mittels Mikropumpe
DE102006047613A1 (de) * 2006-10-07 2008-04-10 Sanofi-Aventis Deutschland Gmbh Peristaltische Mikropumpe mit wechselbarem Pumpenkopf
ES2744384T3 (es) 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
CA2697057A1 (en) * 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
WO2010023666A2 (en) 2008-08-28 2010-03-04 Medingo Ltd. Device and method for enhanced subcutaneous insulin absorption
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
FR2943538B1 (fr) 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
US20120094902A1 (en) 2009-03-27 2012-04-19 Adocia Fast-acting insulin formulation
WO2010149772A1 (en) 2009-06-26 2010-12-29 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and an amino acid
CN102655866B (zh) 2009-11-13 2013-11-13 东丽株式会社 糖尿病的治疗或预防药
US20120178675A1 (en) 2010-07-07 2012-07-12 Biodel Inc. Compositions And Methods For Modulating The Pharmacokinetics and Pharmacodynamics of Insulin
RU2013130374A (ru) 2010-12-14 2015-01-20 Ново Нордиск А/С Препарат, содержащий инсулин, никотинамид и аминокислоту
EP2720713A2 (en) 2011-06-17 2014-04-23 Halozyme, Inc. Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
JP5912426B2 (ja) * 2011-11-07 2016-04-27 ヤマハ発動機株式会社 リニアコンベア
PT3130347T (pt) 2011-12-30 2019-12-10 Halozyme Inc Variantes de polipéptidos de ph20, suas formulações e utilizações
US9399065B2 (en) 2012-04-16 2016-07-26 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin
US9381247B2 (en) 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
US20150174209A1 (en) 2012-05-25 2015-06-25 Amylin Pharmaceuticals. Llc Insulin-pramlintide compositions and methods for making and using them
US20150065423A1 (en) * 2013-08-30 2015-03-05 Perosphere, Inc. Rapid acting injectable formulations
KR102351111B1 (ko) 2014-01-13 2022-01-14 써멀린 다이어비티즈, 엘엘씨 초속효성 인슐린 제형 및 약제학적 전달 시스템
US20150273022A1 (en) 2014-02-10 2015-10-01 Biodel Inc. Stabilized ultra-rapid-acting insulin formulations
JO3624B1 (ar) * 2014-05-08 2020-08-27 Lilly Co Eli تركيبات إنسولين سريعة المفعول
AR102869A1 (es) 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
US20180221385A1 (en) 2015-07-28 2018-08-09 Societe De Commercialisation Des Produits De La Recherche Appliquee Socpra Sciences Sante Et A pharmaceutical preparation for improving absorption and postprandial hypoglycemic action of insulin
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول

Also Published As

Publication number Publication date
MA42701B1 (fr) 2023-01-31
NZ739338A (en) 2019-06-28
TN2018000056A1 (en) 2019-07-08
EP3340966B1 (en) 2022-10-12
ZA201800511B (en) 2019-07-31
MD3340966T2 (ro) 2023-04-30
SV2018005643A (es) 2018-10-09
FI3340966T3 (fi) 2023-01-13
TW201717997A (zh) 2017-06-01
CN107920992A (zh) 2018-04-17
PT3340966T (pt) 2022-12-05
DK3340966T3 (da) 2022-10-24
JP6359780B2 (ja) 2018-07-18
CL2018000503A1 (es) 2018-08-03
MX2018002482A (es) 2018-06-15
CN107920992B (zh) 2021-06-18
PH12018500422B1 (en) 2018-08-29
AR105712A1 (es) 2017-11-01
DOP2018000059A (es) 2018-04-15
LT3340966T (lt) 2022-11-25
ECSP18014922A (es) 2018-04-30
CA2994427C (en) 2019-07-09
IL256939B (en) 2019-10-31
WO2017034956A1 (en) 2017-03-02
EA033396B1 (ru) 2019-10-31
TWI614025B (zh) 2018-02-11
US10925931B2 (en) 2021-02-23
AU2016310475A1 (en) 2018-02-15
US20210169988A1 (en) 2021-06-10
US20180140676A1 (en) 2018-05-24
PL3340966T3 (pl) 2023-01-30
JO3749B1 (ar) 2021-01-31
JP2018172404A (ja) 2018-11-08
HUE060626T2 (hu) 2023-03-28
CA2994427A1 (en) 2017-03-02
JP6935364B2 (ja) 2021-09-15
HRP20221367T1 (hr) 2023-01-06
PE20180782A1 (es) 2018-05-07
PH12018500422A1 (en) 2018-08-29
BR112018001755A2 (pt) 2018-09-18
EP4169505A1 (en) 2023-04-26
MA42701A (fr) 2018-07-04
ES2928664T3 (es) 2022-11-21
IL256939A (en) 2018-03-29
CO2018002026A2 (es) 2018-05-21
EA201890343A1 (ru) 2018-07-31
RS63731B1 (sr) 2022-12-30
KR20180033276A (ko) 2018-04-02
JP2018507869A (ja) 2018-03-22
UA120142C2 (uk) 2019-10-10
MY195781A (en) 2023-02-13
KR102018998B1 (ko) 2019-09-05
US9901623B2 (en) 2018-02-27
AU2016310475B2 (en) 2018-10-18
US20170056478A1 (en) 2017-03-02
EP3340966A1 (en) 2018-07-04

Similar Documents

Publication Publication Date Title
DOP2018000059A (es) Composiciones de insulina de rápida acción
CO2017011535A2 (es) Composiciones de ácido obeticólico y métodos de uso
CY1124454T1 (el) Συνθεσεις ινσουλινης ταχειας-δρασης
CL2017003389A1 (es) Composiciones de pienso para animales y usos de las mismas.
CR20170129A (es) Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del hígado graso no alcohólico
BR112017006137A2 (pt) formulação que contém biotensoativo
ECSP16059106A (es) Composiciones de liberación retardada de linaclotida
UY35306A (es) Formulaciones farmacéuticas estabilizadas de análogos de insulina y/o derivados de insulina.
DK3821905T3 (da) Insulin indeholdende farmaceutiske sammensætninger
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
DK3278801T3 (da) Farmaceutisk sammensætning indeholdende mirabegron
BR112017007753A2 (pt) uso de uma composição cosmética que compreende ácido 10-hidroxiesteárico.
AR108616A1 (es) Formulación combinada de tres compuestos antivirales
CO2017004382A2 (es) Composiciones farmacéuticas que comprenden lobeglitazona para administración oral
CL2019003801A1 (es) Nuevas formulaciones orales de belinostato.
CO2019013251A2 (es) Composiciones de insulina de rápida acción
CY1124253T1 (el) Φαρμακευτικη συνθεση που περιεχει δαρουναβιρη και μεθοδος για την παρασκευη αυτης
BR112018005377A2 (pt) método para preparar uma formulação estável
SV2016005282A (es) Nuevos compuestos